Oral Cancer Clinical Trial
Official title:
Oral Cancer Awareness Level in Egypt: a Pilot Cross-sectional Study
NCT number | NCT05604105 |
Other study ID # | ACU-Med1 |
Secondary ID | |
Status | Not yet recruiting |
Phase | |
First received | |
Last updated | |
Start date | December 2022 |
Est. completion date | July 2023 |
Oral cancer is a fatal disease with high prevalence and poor survival rate. Most oral cancer cases can be detected by the patients themselves. So, when a patient is aware of oral caner, the patient would realize its signs and symptom and seek early medical care; therefore, improving the prognosis. To our knowledge, the level of awareness of oral cancer has not been investigated in Egyptian population. Therefore, this study is planned to be a pilot study as a first study in Egypt.
Status | Not yet recruiting |
Enrollment | 5000 |
Est. completion date | July 2023 |
Est. primary completion date | January 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion criteria: - Adult individuals (Age>18 years). Exclusion criteria: - Dental students or dental practitioners; as awareness of the disease is an integral part of their profession. - Oral cancer patients: Individuals who experience currently or previously having oral cancer. - Individuals with mental or communication disabilities. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Ayat Gamal-AbdelNaser | Ahram Canadian University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Level of awareness to oral cancer | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06031337 -
Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study
|
||
Completed |
NCT00158678 -
IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC
|
Phase 3 | |
Completed |
NCT00933387 -
A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma
|
Phase 2 | |
Enrolling by invitation |
NCT05030597 -
Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma
|
N/A | |
Completed |
NCT03682562 -
Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions
|
||
Recruiting |
NCT03684707 -
Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions
|
Phase 4 | |
Recruiting |
NCT06130332 -
Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)
|
Phase 2 | |
Recruiting |
NCT04372914 -
Prevention of Oral DNA Damage by Black Raspberries
|
N/A | |
Active, not recruiting |
NCT03529422 -
Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
|
Phase 2 | |
Recruiting |
NCT03686020 -
Sensitivity and Specificity of Serum and Salivary CYFRA21-1 in the Detection of Malignant Transformation in Oral Potentially Malignant Mucosal Lesions (Diagnostic Accuracy Study)
|
||
Not yet recruiting |
NCT06060288 -
Diagnostic Accuracy of Mobile Phone Imaging Compared to Conventional Clinical Examination for Oral Cancer Screening
|
||
Withdrawn |
NCT00951470 -
Complete Decongestive Therapy (CDT) for Treatment of Head and Neck Lymphedema
|
N/A | |
Completed |
NCT00964977 -
Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis.
|
Phase 3 | |
Completed |
NCT01418118 -
Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery
|
Phase 4 | |
Active, not recruiting |
NCT00232960 -
Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC
|
N/A | |
Recruiting |
NCT05429099 -
Mandibular Reconstruction Preplanning (ViPMR)
|
Phase 2/Phase 3 | |
Completed |
NCT04614896 -
Use of Ultrasound for Measuring Size of Oral Tongue Cancers
|
N/A | |
Recruiting |
NCT03685409 -
Cancer Chemoprevention by Metformin Hydrochloride in Oral Potentially Malignant Lesions
|
Phase 3 | |
Completed |
NCT00402779 -
Erlotinib Prevention of Oral Cancer (EPOC)
|
Phase 3 | |
Recruiting |
NCT05153733 -
Improved Implant for Reconstruction Purposes After Mandibular Resection
|
N/A |